Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)
United European Gastroenterology Journal · 2026-06 · 14 (5)
DOI: 10.1002/ueg2.70244 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 20.06.2026. Verfasst von Giuseppe Costantino und 24 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL‐23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real‐life data are scant. We aimed to evaluate the effectiveness and safety of MIRI in a real‐world setting.
Methods
UC patients from 12 centres of the SN‐IBD were prospectively enrolled. The primary endpoints were clinical response, steroid‐free remission (SFR), and reduction of urgency at week 12 and at week 24. As secondary endpoint, the need for prolonged induction was considered. All patients received 3 infusions at monthly intervals of 300 mg MIRI; in case of inadequate response, the induction period was prolonged. Urgency was determined by means of the Urgency Numerical Rating Scale (UNRS).
Results
One hundred and five patients were included. Previous failures to 2 or more lines of advanced therapies were present in 74% of patients. At week 12, 24% of patients achieved a clinical response and 53% achieved SFR. At week 24 ( n = 71), the rates were 20% and 68%, respectively. The median urgency score decreased from 6 at baseline to 2 at week 12 and to 1 at week 24 ( p < 0.001, both). Prolonged induction was necessary to half of patients. Adverse events were reported in 5% of patients. Treatment failures occurred in 14 patients (13%).
Conclusions
Our real‐life study confirmed the short‐term effectiveness and safety of MIRI in patients with UC especially in relieving bowel urgency. The flexible induction schedule allows an additional gain in response and remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IBD Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- IBD Unit, Villa Sofia-Cervello Hospital, Palermo, Italy.
- Gastroenterology and Hepatology Section, PROMISE, University of Palermo, Palermo, Italy.
- Gastroenterology Unit, AOU Policlinico San Marco, Catania, Italy.
- Gastroenterology Unit, Garibaldi-Nesima Hospital, Catania, Italy.
- Gastroenterology and Endoscopy Unit, ARNAS Civico-Di Cristina-Benfratelli Hospital, Palermo, Italy.
ORCID-Profile: Anna Viola, Maria Cappello
Zitieren
APA
Costantino, G., Viola, A., Iuculano, A., Macaluso, F. S., Voti, R. L., Cappello, M., Antoci, C., Ferracane, C., Sciuto, M., Catarella, D., Parisi, S., Mocciaro, F., Scrivo, B., Distefano, M. E., Vassallo, R., Minissale, M. G., Scalisi, G., Garufi, S., Rao, S., …, & Fries, W. (2026). Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD). United European Gastroenterology Journal, 14(5). https://doi.org/10.1002/ueg2.70244
Vancouver
Costantino G, Viola A, Iuculano A, Macaluso FS, Voti RL, Cappello M, et al. Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD). United European Gastroenterology Journal. 2026;14(5). doi:10.1002/ueg2.70244
BibTeX
@article{Costantino2026,
author = {Costantino, Giuseppe and Viola, Anna and Iuculano, Andrea and Macaluso, Fabio Salvatore and Voti, Raffaele Li and Cappello, Maria and Antoci, Chiara and Ferracane, Concetta and Sciuto, Morena and Catarella, Domenico and Parisi, Stefanie and Mocciaro, Filippo and Scrivo, Barbara and Distefano, Maria Emanuela and Vassallo, Roberto and Minissale, Maria Giovanna and Scalisi, Giuseppe and Garufi, Serena and Rao, Sofia and Muscarella, Stefano and Tortorella, Vincenza and Giangreco, Emiliano and Muscianisi, Marco and Orlando, Ambrogio and Fries, Walter},
title = {Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {5},
doi = {10.1002/ueg2.70244}
}
EUVIMED